Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly ; volume:9 ; number:1 ; day:8 ; month:11 ; year:2023 ; pages:1-8 ; date:12.2023
Schizophrenia ; 9, Heft 1 (8.11.2023), 1-8, 12.2023

Creator: Correll, Christoph U.
Brieden, Andreas
Janetzky, Wolfgang

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41537-023-00405-5

URN: urn:nbn:de:101:1-2024012910153734710156

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 01.12.2025, 4:22 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Correll, Christoph U.
Brieden, Andreas
Janetzky, Wolfgang
SpringerLink (Online service)

Other Objects (12)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

Index

List of Out-Patients

Index

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

Index

List of Out-Patients

Index

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

Index

List of Out-Patients

Index

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Symptomatic, functional and quality of life measures of remission in 194 outpatients with schizophrenia followed naturalistically in a 6-month, non-interventional study of aripiprazole once-monthly

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

List of Out-Patients

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

List of Out-Patients

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study

Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study

Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach

List of Out-Patients

List of Out-Patients

Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)

SYNTHESIS AND CHARACTERIZATION OF N-OXIDES AND METABOLITES OF ANTIPSYCHOTIC DRUG, ARIPIPRAZOLE

Development of Parkinsonism following exposure to aripiprazole: two case reports

Experimental solubility of aripiprazole in supercritical carbon dioxide and modeling

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia

Related objects

Reset password